Get the Stockscreener App
4.155
9.87%
-0.455
Aquestive Therapeutics Inc stock is traded at $4.155, with a volume of 3.97M.
It is down -9.87% in the last 24 hours and down -13.62% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
See More
Previous Close:
$4.61
Open:
$4.67
24h Volume:
3.97M
Relative Volume:
2.40
Market Cap:
$521.50M
Revenue:
$50.27M
Net Income/Loss:
$-68.91M
P/E Ratio:
-6.8905
EPS:
-0.603
Net Cash Flow:
$-44.32M
1W Performance:
-12.71%
1M Performance:
-13.62%
6M Performance:
-2.00%
1Y Performance:
-43.39%
1-Day Range:
$3.99
$4.715
1-Week Range:
$4.57
$4.975
52-Week Range:
$2.93
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
4.155 | 521.50M | 50.27M | -68.91M | -44.32M | -0.603 |
TAK
Takeda Pharmaceutical Co Adr
|
19.58 | 62.55B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.27 | 48.13B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.96 | 43.80B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
78.98 | 32.64B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.61 | 23.49B | 3.17B | 1.29B | 1.01B | 27.09 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Resumed | Oppenheimer | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 - GlobeNewswire Inc.
Aquestive Therapeutics (NasdaqGM:AQST) Stock Forecast & Analyst Predictions - Simply Wall Street
Aquestive Therapeutics (AQST) CEO sells 25,000 shares in preset plan trade - Stock Titan
Aquestive Therapeutics CEO Barber sells $120,487 in shares By Investing.com - Investing.com UK
Aquestive Therapeutics CEO Barber sells $120,487 in shares - Investing.com
Aquestive (NASDAQ: AQST) CCO sells 8,750 shares after exercising options - Stock Titan
Cantor Fitzgerald reiterates Aquestive stock Overweight on Anaphylm profile By Investing.com - Investing.com Canada
Aquestive Therapeutics (AQST) insider adds 2,293 shares - Stock Titan
Aquestive at cantor healthcare conference: anaphylm launch nears By Investing.com - Investing.com Canada
Aquestive at cantor healthcare conference: anaphylm launch nears By Investing.com - Investing.com India
Aquestive at cantor healthcare conference: anaphylm launch nears By Investing.com - Investing.com UK
Aquestive Therapeutics (AQST) CEO boosts stake with warrant exercise - Stock Titan
AQST Stock Price, Quote & News - Syfe
Aquestive Therapeutics (AQST) COO adds shares via warrant exercise - Stock Titan
Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Investors to Inquire about Securities Investigation - ACCESS Newswire
AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out - accessnewswire.com
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences - Investing News Network
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences - manilatimes.net
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect - ACCESS Newswire
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - natlawreview.com
Blue Owl Capital Holdings LP Makes New $3.92 Million Investment in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive Therapeutics Earnings Call Highlights Anaphylm Progress - TipRanks
Latash Investments LLC Acquires New Holdings in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Aquestive Therapeutics: Potential Catalyst On The Horizon (NASDAQ:AQST) - Seeking Alpha
Aquestive (AQST) Q2 2026 Earnings Call Transcript - AOL.com
Aquestive Therapeutics CEO Daniel Barber Sells 25,000 Shares Under Rule 10b5-1 Plan - Kalkine Media
Aquestive (AQST) Closing Snapshot: Records a 0.70% Increase to $4.32 in the Current Update; Technical Focus - Vinanet
Aquestive Therapeutics CEO Daniel Barber disposes of 25,000 common shares worth $107,168 - Bitget
Aquestive (NASDAQ: AQST) CEO sells 25K shares under preset plan - Stock Titan
Aquestive Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Aquestive (NASDAQ: AQST) CCO's 2,714-share tax withholding detailed - Stock Titan
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeut - The National Law Review
2026-08-16 | Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation | NDAQ:AQST | Press Release - Stockhouse
Walleye Capital LLC Purchases New Stake in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Wasatch Advisors LP Has $5.76 Million Position in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive Therapeutics (AQST) Stock Faces Cash Burn Questions As Anaphylm Nears Resubmission - Sahm
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Aquestive Therapeutics Inc (AQST) (Q2 2026) Earnings Call Highlights: Anaphylm Resubmission on ... - Yahoo! Finance Canada
Earnings call transcript: Aquestive Therapeutics tops revenue views in Q2 2026 - Investing.com Nigeria
Aquestive Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aquestive Therapeutics Inc Stock (AQST) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Daniel Barber | Director |
Sep 15 '26 |
Proposed Sale |
4.88 |
50,000 |
244,000 |
0 |
| Korczynski Sherry | Chief Commercial Officer |
Sep 09 '26 |
Option Exercise |
2.65 |
8,750 |
23,188 |
244,439 |
| Korczynski Sherry | Chief Commercial Officer |
Sep 09 '26 |
Sale |
5.22 |
8,750 |
45,675 |
235,689 |
| Sherry M. Korczynski | Officer |
Sep 09 '26 |
Proposed Sale |
5.21 |
8,750 |
45,588 |
0 |
| Barber Daniel | President and CEO |
Aug 17 '26 |
Sale |
4.29 |
25,000 |
107,168 |
585,574 |
| Daniel Barber | Officer |
Aug 17 '26 |
Proposed Sale |
4.25 |
25,000 |
106,250 |
0 |
| Barber Daniel | President and CEO |
Jul 16 '26 |
Sale |
4.00 |
20,369 |
81,509 |
610,574 |
| Barber Daniel | President and CEO |
Jul 15 '26 |
Sale |
4.03 |
4,631 |
18,683 |
630,943 |
| Daniel Barber | Officer |
Jul 15 '26 |
Proposed Sale |
4.04 |
25,000 |
101,000 |
0 |
| Krop Julie | Director |
Jun 23 '26 |
Option Exercise |
0.71 |
25,000 |
17,830 |
25,000 |
5.68%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):